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Edited by Laszlo NagyAbstract Intracerebroventricularly administered angiotensin
(Ang) II and III dose-dependently suppressed food intake in mice
and their anorexigenic activities were inhibited by AT2 receptor-
selective antagonist. Ang II did not suppress food intake in AT2
receptor-knockout mice, while it did signiﬁcantly in wild-type
and AT1 receptor-knockout mice. The suppression of food intake
in AT1 receptor-knockout mice was smaller than that in wild-
type. The anorexigenic activities of Ang II and III were also
blocked by a selective antagonist for prostaglandin EP4 receptor.
Taken together, centrally administered Ang II and III may de-
crease food intake through AT2 receptor with partial involve-
ment of AT1 receptor, followed by EP4 receptor activation,
which is a novel pathway regulating food intake.
 2008 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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system1. Introduction
The renin–angiotensin system (RAS) plays an important role
in the regulation of blood pressure and ﬂuid volume. It has
been revealed that all the components of RAS, including angi-
otensinogen, enzymes responsible for releasing angiotensins
(Ang) and Ang receptors, are present in the central nervous
system (CNS) as well as the peripheral endocrine system
[1,2]. Among the main bioactive peptides of central RAS,
Ang II shows aﬃnities for both AT1 and AT2 receptors, which
are G-protein coupled seven-transmembrane receptors, while
Ang III is slightly more selective for AT2 receptor than Ang
II [2–6]. It is known that the central administration of Ang
II and III increases blood pressure, water intake, salt appetite
and hormone release from the pituitary, and these activities are
mediated by AT1 receptor [2,7,8]. It has been reported that
Ang II suppresses food intake after central infusion [9–11];
however, it has not been clear which receptor mediates the
anorexigenic activity of Ang II. In the current study, we found
that Ang III also suppresses food intake after centrally single*Corresponding author. Fax: +81 774 38 3774.
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doi:10.1016/j.febslet.2008.01.054administration. The potency of anorexigenic activities of Ang
II and III was consistent with their aﬃnity for AT2 receptor.
We thus investigated whether Ang II- and III-induced anorex-
igenic activities were mediated by AT2 receptor using an AT2
receptor-selective antagonist or AT2 receptor-knockout mice.
We also investigated the mechanism of anorexigenic activi-
ties of Ang II and III downstream of AT2 receptor. Prostaglan-
din (PG) E2, a bioactive lipid produced in the CNS of
mammals including humans, has a variety of physiologically
and pathophysiologically central actions on wakefulness,
fever, pain response and food intake [12–16]. PGE2 exerts its
actions through four diﬀerent types of G-protein-coupled
seven-transmembrane receptors, known as EP1, EP2, EP3
and EP4 receptors [17,18]. For example, EP3 and EP4 receptors
mediate the febrile response and wakefulness eﬀect of PGE2,
respectively [13,14]. We have very recently demonstrated that
EP4 receptor activation inhibits food intake in mice [19,20].
In tissue culture derived from the kidney, Ang II was reported
to stimulate PGE2 biosynthesis [21,22]. We then investigated
whether Ang II- and III-induced anorexigenic activities were
coupled to EP4 receptor.2. Materials and methods
2.1. Reagents
Angiotensin II and III were obtained from the Peptide Institute, Inc.
(Osaka, Japan). An AT2 receptor-selective antagonist PD123319 was
purchased from Sigma–Aldrich, Co. (St. Louis, MO). An AT1 recep-
tor-selective antagonist CV-11974 (candesartan) and EP4 receptor
antagonist ONO-AE3-208 were kindly provided by Takeda Pharma-
ceutical Co., Ltd. (Osaka, Japan) and Ono Pharmaceutical Co., Ltd.
(Osaka Japan), respectively [19,23].2.2. Cannula implantation
Male ddY mice at 7 weeks of age were obtained from Japan SLC
(Shizuoka, Japan). Male AT1a receptor-deﬁcient [24], AT2 receptor-
deﬁcient [25] and wild-type C57BL/6J (Clea Japan, Inc., Tokyo, Japan)
mice at 27 weeks of age were also used. Each mouse was individually
housed under regulated conditions (22–24 C on a 12 h light–dark cy-
cle with lights on at 7 a.m.). Mice had free access to food pellets and
water unless otherwise indicated. Intracerebroventricular (i.c.v.)
administration was performed as previously described [19,20,26–28].
Brieﬂy, mice were anesthetized with sodium pentobarbital (80–
85 mg/kg i.p.) and placed in a stereotaxic instrument. A 24-gauge can-
nula beveled at one end over a distance of 3 mm (Safelet-Cas, Nipro,
Osaka, Japan) was implanted 0.9 mm posterior to the bregma and
0.9 mm lateral to the suture for administration into the third cerebral
ventricle. Animals were tested one week or more after implantation.blished by Elsevier B.V. All rights reserved.
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The food intake experiment was performed as previously described
[19,20,26–28]. Angiotensin II or III was dissolved in artiﬁcial cerebro-
spinal ﬂuid (ACSF; 138.9 mM NaCl, 3.4 mM KCl, 1.3 mM CaCl2,
4.0 mM NaHCO3, 0.6 mM NaH2PO4, 5.6 mM glucose, pH 7.4). The
test started at 11 a.m. Mice fasted for 18 h with free access to water
were i.c.v. administered with Ang II or Ang III in 4 ll ACSF or vehicle
alone. AT1 receptor-selective antagonist CV-11974 at a dose of 1 nmol/
mouse was i.c.v. co-administrated with Ang II (1 nmol/mouse) in 4 ll
ACSF. We conﬁrmed that centrally administered Ang II (1 nmol/
mouse)-induced water intake, which was mainly mediated by AT1
receptor, was signiﬁcantly blocked by 1 nmol/mouse of CV-11974
(data not shown), similarly to another AT1 receptor antagonist valsar-
tan as previously described [30]. AT2 receptor antagonist PD123319 at
a dose of 6.5 nmol/mouse [30] in 2 ll ACSF was administered 30 min
before the central administration of Ang II or III (1 nmol/mouse) in
2 ll ACSF. The weight of the food pellets in each cage was measured
at 0 and 20 min and 1, 2 h after i.c.v. administration of Ang II or III,
and the cumulative food intake was calculated. All experiments were
approved by Kyoto University Ethics Committee for Animal Research
Use. All mice were killed by an overdose of anesthesia drugs after the
experiment.
2.4. Statistical analysis
Values are expressed as the means ± S.E.M. Analysis of variance
(ANOVA) followed by Fishers test was used to assess diﬀerences
among groups. P values less than 0.05 were considered signiﬁcant.Fo
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Fig. 1. Eﬀect of central administration of angiotensins (Angs) on food
intake in conscious male ddY mice fasted for 18 h. (a) Ang II (0.03–
1 nmol/mouse), (b) Ang III (0.3–10 nmol/mouse) and Ang IV (1–
10 nmol/mouse) were i.c.v. administered, and cumulative food intake
was measured. Values are the means ± S.E.M. (a, n = 7–8; b, n = 5–7;
c, n = 7). *P < 0.05, **P < 0.01, ***P < 0.001, compared with the ACSF
control group.3. Results
3.1. Centrally administered angiotensin II and III suppress food
intake
Ang II dose-dependently suppressed food intake at a dose of
0.1–1 nmol/mouse 20 min after i.c.v. administration in male
ddY mice fasted for 18 h, and the anorexigenic eﬀect lasted
for 60 min (Fig. 1a). Ang III also decreased food intake at a
dose of 0.3–10 nmol/mouse 60 min after central administration
in a dose-dependent manner (Fig. 1b). Ang III was reported to
have 10-fold or 3-fold less potent aﬃnity for AT1 receptor or
AT2 receptor, respectively, than Ang II [6]. The minimum
eﬀective dose for the anorexigenic eﬀect of Ang II (0.1 nmol/
mouse) 20 min after administration was approximately one-
third of Ang III (0.3 nmol/mouse) 60 min after administration.
Ten nmol/mouse of Ang IV was inactive under our experimen-
tal condition (Fig. 1c). These results raise the possibility that
AT2 receptor activations might induce the suppression of food
intake.
3.2. Anorexigenic activities of angiotensin II and III are mainly
mediated by AT2 receptor
We investigated whether Ang II- and III-induced anorexi-
genic eﬀects are mediated by AT2 or AT1 receptor using their
receptor-selective antagonists. AT2 receptor-selective anta-
gonist PD123319 (6.5 nmol/mouse, i.c.v.) signiﬁcantly
(P < 0.01) inhibited two-third of the anorexigenic activity of
Ang II (1 nmol/mouse, i.c.v.) in male ddY mice, as shown in
Fig. 2b. On the other hand, AT1 receptor antagonist CV-
11974 (1 nmol/mouse, i.c.v.) tended to block the anorexigenic
activity of Ang II (1 nmol/mouse, i.c.v.) (P = 0.134, control
vs Ang II with CV-11974); however, this was not signiﬁcant
(P = 0.117, Ang II with vs without CV-11974) (Fig. 1a). These
results suggest that the anorexigenic activity of Ang II, which
shows aﬃnity for both AT1 and AT2 receptors, is mainly med-
iated by AT2 receptor, though the contribution of AT1 recep-
tor is unclear. The anorexigenic eﬀect of Ang III (1 nmol/mouse, i.c.v.), which was more selective for AT2 receptor than
Ang II, was completely blocked by PD123319 (6.5 nmol/
mouse, i.c.v.) (Fig. 2c), suggesting that Ang III suppresses food
intake via AT2 receptor.
To determine contribution of AT2 and AT1 receptors to the
Ang II-induced anorexigenic activity, we also used the AT2
and AT1 receptors-knockout and wild-type C57BL/6 J mice.
Ang II (1 nmol/mouse) did not suppress food intake 60 min
after i.c.v. administration in AT2 receptor-knockout mice,
while did it in AT1 receptor-knockout and wild-type mice
(Fig. 3). However, the suppression of food intake by Ang II
in AT1 receptor-knockout mice was signiﬁcantly smaller than
that in wild-type mice, which was consistent with eﬀect of
AT1 antagonist, suggesting that Ang II-induced anorexigenic
activity is partly mediated through AT1 receptor. Taken
together, AT2 receptor activation led to suppression of food
intake by Ang II with partial involvement of AT1 receptor.
3.3. Anorexigenic activities of angiotensin II and III are
mediated by prostaglandin E2-EP4 receptor
Centrally administered PGE2 suppresses food intake via EP4
receptor among four subtypes for PGE2. The anorexigenic
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Fig. 2. Eﬀect of a selective antagonist for AT1 or AT2 receptor on the
anorexigenic activity of Ang II or III after central administration. (a)
AT1 receptor-selective antagonist CV-11974 (1 nmol/mouse) or (b and
c) AT2 receptor-selective antagonist PD123319 (6.5 nmol/mouse) was
i.c.v. administered with (a and b) Ang II or (c) Ang III at a dose of
1 nmol/mouse in ddY mice fasted for 18 h. Food intake was measured
for (a and c) 20 min and (b) 60 min. Values are presented as the
means ± S.E.M. (n = 7–8). *P < 0.05, **P < 0.01, compared with the
control group.
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Fig. 3. Suppression of food intake in wild-type C57BL/6 J, AT1
receptor-knockout and AT2 receptor-knockout mice. Each male
mouse fasted for 18 h was i.c.v. administered with Ang II at a dose
of 1 nmol/mouse, and food intake was measured for 60 min. Values are
presented as the means ± S.E.M. (n = 8–17). *P < 0.05, **P < 0.01,
***P < 0.001, compared with the control group.
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by an EP4 receptor-selective antagonist ONO-AE3-208
(10 nmol/mouse, i.c.v.) in fasted ddY mice (Fig. 4a and b). Ta-
ken together, we demonstrated that Ang II and III decreased
food intake via PGE2 production and EP4 receptor activation.Fig. 4. Eﬀect of an EP4 receptor antagonist on the anorexigenic
activity of Ang II or III. An EP4 receptor-selective antagonist ONO-
AE3-208 (10 nmol/mouse, i.c.v.) was administered 30 min before Ang
II or III (1 nmol/mouse, i.c.v.) in male ddY mice fasted for 18 h, and
food intake was measured for 60 min. Values are presented as the
means ± S.E.M. (n = 6–7). *P < 0.05; **P < 0.01, ***P < 0.001 com-
pared with each group.4. Discussion
We found that not only Ang II but also Ang III suppress
food intake after central administration to fasted mice. The
aﬃnities of Ang III and II for the AT2 receptor are consistent
with their anorexigenic activities. Blockade of the AT2 receptor
using a selective antagonist and knockout mice abolished the
suppression of food intake of centrally administered Ang ago-
nist peptides. We thus demonstrated for the ﬁrst time that acti-
vation of the central AT2 receptor induced food intake
suppression.
The Ang system, including angiotensin I-converting enzyme
(ACE), and Ang II and Ang receptors (AT1 and AT2 recep-tors), are localized in the hypothalamus in the CNS [1,2,29],
which is known to play important roles in not only regulating
food intake but also water intake and blood pressure [1,2]. The
AT2 receptor, which mediates anorexigenic activities of Ang
agonist peptides such as Ang II and III, was reported to be
present in the paraventricular nucleus (PVN) of the hypothal-
amus using in situ autoradiography [29]. AT1 receptor, which
776 K. Ohinata et al. / FEBS Letters 582 (2008) 773–777is mainly associated with water intake, blood pressure regula-
tion and vasopressin secretion [2], was detected in the PVN,
suprachiasmatic nucleus, and median eminence of the hypo-
thalamus in the CNS [29].
AT1 receptor often functionally interacts with AT2 receptor
in the CNS. For example, centrally administered Ang II in-
creased systolic blood pressure in wild-type and AT2 recep-
tor-knockout mice; however, this increase was signiﬁcantly
greater in AT2-knockout mice than in WT mice [30]. On the
other hand, stimulation of water intake-induced by Ang II
was partly suppressed in both AT1 receptor- and AT2 recep-
tor-knockout mice, although the suppressive eﬀect in AT1-
knockout mice was more potent than that in AT2 receptor-
knockout mice. These results indicate that central AT1 and
AT2 receptors act reversely each other in blood pressure regu-
lation, while they act synergistically in water intake regulation
[30]. In the current study, centrally administered Ang II sup-
pressed food intake in wild-type and AT1 receptor-knockout
mice but not in AT2 receptor-knockout mice; however, the
anorexigenic activity of Ang II in AT1 receptor-knockout mice
less potent than that in wild-type mice. These results suggest
that AT1 receptor partly mediates Ang II-induced anorexigenic
activity, though its contribution is smaller than that of AT2
receptor. Thus, the anorexigenic activities of Ang II after cen-
tral administration may be mainly mediated via AT2 receptor
with partial involvement of AT1 receptor.
We also found that an AT2 receptor-selective agonist peptide
novokinin [31], which we designed as an orally active hypoten-
sive peptide, decreased food intake both in wild-type and AT1
receptor-knockout mice to the same extent, while it was inac-
tive in AT2 receptor-knockout mice (unpublished data). This
suggests that the anorexigenic activity of novokinin is medi-
ated by AT2 receptor.
We have recently demonstrated that the activation of EP4
receptor among PGE2 receptors inhibits food intake in mice
[19,20]; however, the pathways upstream of EP4 receptor have
been unclear. Anorexigenic activities of Ang II and III after
central administration were inhibited by EP4 receptor, indicat-
ing that AT2 receptor is coupled to the PGE2-EP4 receptor sys-
tem. In the hypothalamus, EP4 receptor mRNA was
abundantly localized in the PVN and the supraoptic nucleus
[17,32], where the AT2 receptor also exists [29]. PGE2 is pro-
duced from arachidonic acid by cyclooxygenase (COX) fol-
lowed by PGE synthase, and acts near to its production site
[17,33]. It was reported that COX and PGE synthase are con-
stitutively present in the PVN [33]. In the current study, we
demonstrated that the PGE2-EP4 receptor was coupled down-
stream of AT2 receptor, and this signal transduction is a novel
pathway regulating food intake in the CNS.
It has recently been reported that some AT1 antagonists by
themselves suppress food intake [34]. After AT1 receptor
antagonist administration, endogenous Ang II, having aﬃni-
ties for both AT1 and AT2 receptors, might act as an AT2
receptor agonist. From our results, this AT2 receptor activa-
tion might be one explanation for the anorexigenic activities
of AT1 receptor antagonists.
In conclusion, we found that exogenously administered Ang
II and III decrease food intake after central administration.
Blockages of angiotensin AT2 receptor using a selective antag-
onist and knockout mice abolished the anorexigenic activities
of centrally administered Ang II and III. These results suggest
that activation of central AT2 receptor suppresses food intake.Furthermore, the Ang II- and III-induced anorexigenic actions
were inhibited by an EP4 receptor antagonist. Taken together,
the AT2 receptor might be coupled to the PGE2-EP4 receptor
system in food intake regulation in the CNS.Acknowledgements: This work was supported, in part, by Grants-in-
Aid for Scientiﬁc Research from Japanese Society for Promotion of
Science to M.Y. and K.O., and a PROBRAIN Grant from the Bio-ori-
ented Technology Research Advancement Institution to M.Y.References
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